60
Participants
Start Date
September 30, 2002
Primary Completion Date
February 2, 2023
Study Completion Date
February 2, 2023
temozolomide followed by high dose busulfan and thiotepa
Temozolomide 200mg/m2 PO Days 1-5 recycled every 28 days Day minus -8 thiotepa 250 mg/m2 intravenously Day minus -7 thiotepa 250 mg/m2 intravenously Day minus -6 thiotepa 250 mg/m2 intravenously Day minus -5 busulfan 3.2 mg/kg intravenously over two hours Day minus -4 busulfan 3.2 mg/kg intravenously over two hours Day minus -3 busulfan 3.2 mg/kg intravenously over two hours Day minus -2 rest Day minus -1 rest Day 0 peripheral blood stem cell or bone marrow reinfusion
Memorial Sloan Kettering Cancer Center, New York
Memorial Sloan Kettering Cancer Center, Basking Ridge
Memorial Sloan Kettering Cancer Center, Commack
Collaborators (1)
University of Calgary
OTHER
Northwestern University
OTHER
Northwestern Memorial Hospital
OTHER
Massachusetts General Hospital
OTHER
Schering-Plough
INDUSTRY
Memorial Sloan Kettering Cancer Center
OTHER